Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236922 | 1.00 | ALOX15 (0.50) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL1769633 | 0.95 | DPP4 (0.49) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL1769630 | 0.95 | DPP4 (0.49) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL21689946 | 0.90 | GLA (0.50) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL13687942 | 0.86 | DPP4 (0.46) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL4145023 | 0.86 | DPP4 (0.52) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL27734662 | 0.86 | DPP4 (0.52) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL4156032 | 0.86 | DPP4 (0.52) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| SCHEMBL14254554 | 0.86 | DPP4 (0.46) | ALOX15TSHRHSD17B10DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL4017917 | 0.85 | DPP4 (0.46) | ALOX15TSHRHSD17B10DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-01-20 | — | — | US | disclosed |
| CN-114096250-B | Therapies for erythropoiesis protoporphyria (EPP) and X-linked protoporphyria (XLP) | 匹兹堡大学 联邦高等教育系统 | 2025-01-14 | — | — | CN | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | disclosed |
| EP-3972605-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114096250-A | Novel therapy for erythropoietic protoporphyrinopathy (EPP) and X-linked protoporphyrinopathy (XLP) | 匹兹堡大学联邦高等教育系统 | 2022-02-25 | — | — | CN | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| WO-2020236901-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-11-26 | — | — | WO | disclosed |
| US-9109009-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2013-08-29 | — | — | US | disclosed |
| CN-102844327-A | Template-fixed peptidomimetics with CXCR7 modulatory activity | POLYPHOR AG | 2012-12-26 | — | — | CN | disclosed |
| EP-2531520-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | Polyphor AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| CN-102712676-A | Template-fixed peptidomimetics with CCR10 antagonistic activty | POLYPHOR AG | 2012-10-03 | — | — | CN | disclosed |
| WO-2011095607-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20090068718-A1 | AMINO ACID DERIVATIVES OF INDOLINONE BASED PROTEIN KINASE INHIBITORS | LIANG CONGXIN | 2009-03-12 | — | — | US | disclosed |
| US-20080269212-A1 | Amino acid derivatives of indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ALOX15 2548/4885TSHR 3853/4885HSD17B10 1828/4885 |
| US-12528808-B2 | Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) | ABCC3, ABCC2, ABCB7 | ALOX15 3916/4885TSHR 2892/4885HSD17B10 2171/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX15 2548/4885TSHR 3853/4885HSD17B10 1828/4885 |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | ALOX15 3382/4885TSHR 963/4885HSD17B10 2737/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX15 2548/4885TSHR 3853/4885HSD17B10 1828/4885 |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | XPA, TPX2, XPOT | ALOX15 3859/4885TSHR 3760/4885HSD17B10 3082/4885 |
| US-20080269212-A1 | Amino acid derivatives of indolinone based protein kinase inhibitors | PHKG1, MAP3K20, MKNK1 | ALOX15 4461/4885TSHR 3421/4885HSD17B10 2316/4885 |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | ALOX15 3959/4885TSHR 1105/4885HSD17B10 3813/4885 |
| US-20090068718-A1 | AMINO ACID DERIVATIVES OF INDOLINONE BASED PROTEIN KINASE INHIBITORS | PHKG1, MAP3K20, MKNK1 | ALOX15 4461/4885TSHR 3421/4885HSD17B10 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.